Divea, so i've spent my morning looking over the resume of Dr. Dhillon as you made me realize that I was actually not comfortable with my knowledge of ARTH's board of directors.
I do not see your perspective on the following:
1) Inovio: President and CEO. Current mkt cap of 483m. Company traded sub $2 when he took over. Traded up to $20 by 2005.
2) MDS Capital Corp. (Lumira Capital Corp.): VP
3) Cardiome Pharma Corp: Consultant. Company went on to trade at market cap of almost $1.8b by 2005.
4) Protox Therapeutics: Founding board member. Company tripled in first 2 years. He left after securing financing in 2010. Company sidelined until 2014 and ultimately declined.
5) BC Advantage Funds: Mentor/Director.
Regarding the following OTC stocks you mentioned:
1) Stevia First. This is essentially a dietary start-up focussing on a new form of artificial sweetener. This is a far cry from the MIT licensed technology and potential behind AC5. Were you investing in Stevia? If so, I would love to hear why...
2) OncoSec Medical, INC. This company is developing DNA-based immunotherapy to treat tumors/cancers. Dhillon served as the Chairman of the Board of Directors, yes. He was brought on after the stock declined from above $30 to sub $4. Brought in to help realign the corporate mission perhaps? He was brought in as the stock was collapsing.
Lastly,
There are two red flags that I have come across with ARCH. 1, the company went public via reverse merger and 2, the 2013 pump article.
Here is what I will say. 1, Dr. Norchi was interviewed on the reverse merger. His answer basically states that it was 2008-2009 where the financial crisis had all but eliminated access to capital. Reverse Merger was the cheapest way to compete. 2, There was never any connection made between ARCH and the stock promoting publication. It is assumed an equity owner promoted this company themselves.
One additional point, ARCH refinanced their outstanding debt to pay it down 1 year earlier at better terms. What company would do that other than one focused on efficient capital allocation.
